Financial Comparison: Amyris (AMRS) versus The Competition

Amyris (NASDAQ: AMRS) is one of 25 publicly-traded companies in the “Industrial organic chemicals” industry, but how does it weigh in compared to its rivals? We will compare Amyris to related businesses based on the strength of its profitability, risk, valuation, analyst recommendations, earnings, institutional ownership and dividends.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Amyris has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Amyris’ rivals have a beta of 0.49, indicating that their average share price is 51% less volatile than the S&P 500.

Earnings and Valuation

This table compares Amyris and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amyris $143.45 million -$77.39 million -2.18
Amyris Competitors $3.36 billion $346.13 million 4.22

Amyris’ rivals have higher revenue and earnings than Amyris. Amyris is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

22.3% of Amyris shares are held by institutional investors. Comparatively, 52.8% of shares of all “Industrial organic chemicals” companies are held by institutional investors. 11.3% of Amyris shares are held by company insiders. Comparatively, 14.0% of shares of all “Industrial organic chemicals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Amyris and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amyris -53.95% N/A -96.89%
Amyris Competitors -11.48% -11.19% -5.31%

Analyst Ratings

This is a breakdown of current recommendations for Amyris and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amyris 0 1 2 0 2.67
Amyris Competitors 120 477 741 26 2.49

Amyris currently has a consensus target price of $9.67, suggesting a potential upside of 45.15%. As a group, “Industrial organic chemicals” companies have a potential upside of 9.36%. Given Amyris’ stronger consensus rating and higher possible upside, equities analysts clearly believe Amyris is more favorable than its rivals.


Amyris rivals beat Amyris on 9 of the 13 factors compared.

About Amyris

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with's FREE daily email newsletter.

Leave a Reply